- Home
- TDOC vs AUPH Comparison
TDOC vs AUPH Comparison
Compare TDOC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDOC
- AUPH
- Stock Information
- Founded
- TDOC 2002
- AUPH 1993
- Country
- TDOC United States
- AUPH Canada
- Employees
- TDOC N/A
- AUPH N/A
- Industry
- TDOC Medical/Nursing Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- TDOC Health Care
- AUPH Health Care
- Exchange
- TDOC Nasdaq
- AUPH Nasdaq
- Market Cap
- TDOC 1.4B
- AUPH 1.6B
- IPO Year
- TDOC 2015
- AUPH 1999
- Fundamental
- Price
- TDOC $8.58
- AUPH $11.63
- Analyst Decision
- TDOC Buy
- AUPH Strong Buy
- Analyst Count
- TDOC 17
- AUPH 2
- Target Price
- TDOC $9.97
- AUPH $13.00
- AVG Volume (30 Days)
- TDOC 9.3M
- AUPH 1.6M
- Earning Date
- TDOC 10-29-2025
- AUPH 11-06-2025
- Dividend Yield
- TDOC N/A
- AUPH N/A
- EPS Growth
- TDOC N/A
- AUPH N/A
- EPS
- TDOC N/A
- AUPH 0.42
- Revenue
- TDOC $2,542,268,000.00
- AUPH $260,111,000.00
- Revenue This Year
- TDOC $0.09
- AUPH $17.33
- Revenue Next Year
- TDOC $1.09
- AUPH $14.31
- P/E Ratio
- TDOC N/A
- AUPH $27.74
- Revenue Growth
- TDOC N/A
- AUPH 25.59
- 52 Week Low
- TDOC $6.35
- AUPH $6.55
- 52 Week High
- TDOC $15.21
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- TDOC 51.61
- AUPH 48.14
- Support Level
- TDOC $8.26
- AUPH $11.30
- Resistance Level
- TDOC $8.99
- AUPH $11.85
- Average True Range (ATR)
- TDOC 0.56
- AUPH 0.36
- MACD
- TDOC -0.04
- AUPH 0.04
- Stochastic Oscillator
- TDOC 35.76
- AUPH 67.94
About TDOC Teladoc Health Inc.
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with improved convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.